Rucotinib combined with artificial liver for severe hepatic graft-versus-host disease with poor glucocorticoid response:A report of 3 cases

Abstract

Abstract: Objective To observe the efficacy of Rucotinib combined with artificial liver in the treatment of 3 cases of severe liver graft-versus-host disease(GVHD) with poor glucocorticoid response. Methods A total of 3 patients with severe liver graft-versus-host disease after allogeneic hematopoietic stem cell transplantation were retrospectively collected from January 2017 to December 2021 in the Infectious disease Department of Affiliated Hospital of Guizhou Medical University. All 3 patients were treated with Rucotinib combined with artificial liver, and received active infection prevention and symptomatic treatment. Results Three patients with severe liver GVHD were treated with Rucotinib combined with artificial liver PE and DPMAS, and the liver function was significantly improved and the prognosis was favorable. Conclusion The prognosis of liver graft-versus-host disease is poor, and early diagnosis and treatment are essential. The abnormal elevation of ALP and glutamyltranspeptide before total bilirubin after allogeneic hematopoietic stem cell transplantation may serve as an important early warning indicator of chronic liver GVHD. Early treatment with rucotinib can improve the over-activation of immune system, reduce the damage of bile duct epithelial cells, thereby reducing liver damage, avoiding artificial liver treatment, and prolonging the survival time of patients.

Key words: Ruxolitinib, Artificial liver, Glucocorticoid, Graft versus host disease

ZHOU Xing-nian, ZHAO Peng, GAO Ting, ZHANG Quan, LI Hong. Rucotinib combined with artificial liver for severe hepatic graft-versus-host disease with poor glucocorticoid response:A report of 3 cases[J]. Chinese Hepatolgy, 2025, 30(2): 240-244.

References

[1] Axt L, Naumann A, Toennies J, et al. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation[J]. Bone Marrow Transplant,2019,54(11):1805-1814.
[2] Zeiser R, Von Bubnoff N, Butler J, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease[J]. N Engl J Med,2020,382(19):1800-1810.
[3] Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease[J]. N Engl J Med,2021,385(3):228-238.
[4] Ramachandran V, Kolli S S, Strowd L C. Review of Graft-Versus-Host Disease[J]. Dermatol Clin,2019,37(4):569-582.
[5] Matsukuma K E, Wei D, Sun K, et al. Diagnosis and differential diagnosis of hepatic graft versus host disease (GVHD) [J]. Gastrointest Oncol,2016,7(Suppl 1):S21-31.
[6] Yang A H, Han M A T, Samala N, et al. Characterization of Hepatic Dysfunction in Subjects Diagnosed With Chronic GVHD by NIH Consensus Criteria[J]. Transplant Cell Ther,2022,28(11):747.e741-747.e710.
[7] Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans[J]. Blood,2012,119(6):1570-1580.
[8] Jagasia M H, Greinix H T, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report[J]. Biol Blood Marrow Transplant, 2015,21(3):389-401.e1.
[9] Filipovich A H, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant,2005,11(12):945-956.
[10] 中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ)——急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志,2020,41(7):529-536.
[11] 中华医学会血液学分会造血干细胞应用学组, 中国抗癌协会血液病转化委员会. 慢性移植物抗宿主病(cGVHD)诊断与治疗中国专家共识(2021年版)[J]. 中华血液学杂志,2021,42(4):265-275.
[12] Shulman H M, Cardona D M, Greenson J K, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. [J]. Biol Blood Marrow Transplant,2015,21(4):589-603.
[13] Larsen F S, Schmidt L E, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol,2016,64(1):69-78.
[14] Kaplan AA. Moderator's view: High-volume plasma exchange: pro, con and consensus[J]. Nephrol Dial Transplant,2017,32(9):1464-1467.
[15] Yin G C, Ya C M, Li Q, et al. Clinical experience of double plasma molecular absorption with a combination of two hemoperfusion machines in treatment of liver failure[J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2013,25(12):738-42.
[16] Yan G S, Li L L, Jiang S L, et al. Clinical study of different adsorbents with dual plasma molecular adsorption system in the treatment of hepatic failure[J]. Zhonghua Gan Zang Bing Za Zhi,2019,27(1):51-55.
[17] Guo X, Wu F, Guo W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure[J]. J Int Med Res,2020,48(6):300060520932053.
[18] 中华医学会肝病学分会重型肝病与人工肝学组, 白浪, 陈煜, 等. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 实用肝脏病杂志,2022,25(03):457-468.
[19] Shaker M E, Hazem S H, Ashamallah S A. Inhibition of the JAK/STAT pathway by ruxolitinib ameliorates thioacetamide-induced hepatotoxicity[J]. Food Chem Toxicol,2016,96(290-301).
[20] Song Z, Liu X, Zhang W, et al. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2[J]. Transl Med,2022,20(1):157.
[21] Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey[J]. Leukemia,2015,29(10):2062-2068.
[22] Verstovsek S, Mesa R A, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis[J]. N Engl J Med,2012,366(9):799-807.
[23] Harrison C, Kiladjian J J, Al-Ali H K, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis[J]. N Engl J Med,2012,366(9):787-798.